← Home / Corvus Pharmaceuticals, Inc. (CRVS)
Stock Analysis
Corvus Pharmaceuticals, Inc. (CRVS)
CRVS
CRVS · Market data
13.26 +0.53%
Track CRVS in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when CRVS price is:
52W Range Position
43%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-02 16:46 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 13.83. Holding above 13.26 keeps the current thesis intact.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
13.26
↗
Break Above
Confirmation improves above resistance.
13.83
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 13.26
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
22
●
Management / Board
MEDIUM
CRVS board and management update
Clark delivered notice of his intention to resign from the board of directors (the “Board”) of Corvus Pharmaceuticals, Inc.
8-K Filing • SEC EDGAR
MAY
7
●
Financial Results
HIGH
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
(Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2026.
8-K Filing • SEC EDGAR
What's Driving CRVS?
📈 Technical recovery is improving
Momentum is Neutral. Watch 13.83 for confirmation and 13.26 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 12.54 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Downtrend Structure
Downtrend line not broken yet · score 0
Trigger
15.00
RSI(14)
44.2
◎
How to read this setup
The next meaningful technical decision is likely to occur between support at 12.54 and resistance at 13.83. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
CRVS — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$1.1B
Company size
EV
$1.1B
Debt-adjusted value
P/B
4.6
Balanced
EV/EBIT
-22.4
Not meaningful
P/FCF
-31.7
Not meaningful
FCF Yield
-3.15%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
📈 Net Income
-13.69M
≈ Insufficient
🧮 EPS (Basic)
-0.15
≈ Insufficient
Corvus Pharmaceuticals, Inc.
Related Opportunities